FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BARR JOHN						2. Issuer Name and Ticker or Trading Symbol AP PHARMA INC /DE/ [APPA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last)	Last) (First) (Middle)												X	Officer (g	ive title		Other (spelow)	pecify
					3. Date of Earliest Transaction (Month/Day/Year)									Vie	ce Presid	lent of	f R&D	
A.P. PHARMA, INC. 123 SAGINAW DRIVE					07/08/2011													
125 5AC	JINAW DK	IVE																
(Street) REDWOOD CITY CA		94063		4. If Amendment, Date of Original Filed (Month/Day/Year)							6.	5. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(City) (State) (Zi		(Zip)	-		Form filed by Mor							u by More	e ulaii C	эне кероп	ig r erson		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date			Transact ate Month/Day		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.			Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		or 5. Amount Securities Beneficial Owned Fo		Form ly (D) c		n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership	
							Code	v	Amount	ount (A) or (D)		!	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. r) 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amou Securities Underl Derivative Securi (Instr. 3 and 4)		ying Derivative		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable		piration ate	Title	Amount of Number of Shares			(Instr. 4)			
Incentive Stock Option (right to buy)	\$0.26	07/08/2011		A		677,697		(1)	07	7/08/2021	Common Stock	677,69	97	\$0	677,6	97	D	
Non- Qualified Stock Option (right to	\$0.26	07/08/2011		A		6,322,303		(1)	07	7/08/2021	Common Stock	6,322,3	303	\$0	6,322,3	303	D	

Explanation of Responses:

1. Grant vests monthly over a 4 year period and will fully vest on July 8, 2015.

By: Natalie Godfrey, Attorneyin-fact For: John Barr 07/12/2011

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.